Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 First-in-Human Trial of DS3610a in Advanced Solid Tumors
jRCT2031250388Phase 1Recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Oct 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of DS3610 in Nonhematologic neoplasms and Metastatic solid neoplasm, sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Dose Limiting Toxicities. Started Oct 2025; status: recruiting.
02
Drugs
DS3610
03
Conditions
Nonhematologic neoplasmsMetastatic solid neoplasm
Beyond the preview
Go deeper on jRCT2031250388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250388.